Overview
Syngulon develops original genetic technologies using bacteriocins to improve microbial fermentation. The company operates as a 'Startup in the Labs,' working directly in academic partner laboratories across Belgium, Brazil, France, Germany, The Netherlands, and the UK. Bacteriocins are ribosomally-produced, genetically encoded antimicrobial peptides that can be modified using synthetic biology.
In the news
- A milestone worth celebrating: Syngulon has reached 2 500 followers on LinkedIn! Thank you to everyone following our work and developments in 𝗮𝗻𝘁𝗶𝗯𝗶𝗼𝘁𝗶𝗰-𝗳𝗿𝗲𝗲 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝗼𝗻, bacteriocins for 𝗰𝗼𝗻𝘁𝗮𝗺𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝗰𝗼𝗻𝘁𝗿𝗼𝗹, and 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀. We truly appreciate your interest, interactions and support — and look forward to sharing the next developments with you. Thank you for being part of the Syngulon community! #SyntheticBiology #AntibioticFree #AMR #bacteriocins
- Syngulon at the 2026 AFCC Biobased Economy Conference We are pleased to announce that Guy Hélin, CEO, will speak at the 2026 AFCC Biobased Economy Conference on November 2 in Washington, D.C. (USA). His presentation: “𝗣𝗿𝗼𝗴𝗿𝗮𝗺𝗺𝗶𝗻𝗴 𝗺𝗶𝗰𝗿𝗼𝗯𝗶𝗮𝗹 𝗰𝗼𝗻𝘁𝗿𝗼𝗹: 𝗯𝗮𝗰𝘁𝗲𝗿𝗶𝗼𝗰𝗶𝗻𝘀 𝗳𝗼𝗿 𝗿𝗼𝗯𝘂𝘀𝘁, 𝗮𝗻𝘁𝗶𝗯𝗶𝗼𝘁𝗶𝗰-𝗳𝗿𝗲𝗲 𝗯𝗶𝗼𝗯𝗮𝘀𝗲𝗱 𝗯𝗶𝗼𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴” Industrial fermentation faces two persistent challenges: maintaining stable production systems and controlling microbial
- 𝗕𝗮𝗰𝘁𝗲𝗿𝗶𝗼𝗰𝗶𝗻 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 | 𝗝𝘂𝗹𝘆-𝗔𝘂𝗴𝘂𝘀𝘁 𝟮𝟬𝟮𝟲 Bacteriocin research continues to reveal both new antimicrobial molecules and new insights into the biological roles these peptides can play in microbial ecosystems. In our latest Scientific Highlights, we selected two recent studies: 🔬 𝗣𝘂𝗺𝗶𝗰𝘆𝗰𝗹𝗶𝗻 𝗔 𝗲𝘅𝗽𝗮𝗻𝗱𝘀 𝘁𝗵𝗲 𝗴𝗿𝗼𝘄𝗶𝗻𝗴 𝗳𝗮𝗺𝗶𝗹𝘆 𝗼𝗳 𝗵𝗶𝗴𝗵𝗹𝘆 𝘀𝘁𝗮𝗯𝗹𝗲 𝗰𝗶𝗿𝗰𝘂𝗹𝗮𝗿 𝗯𝗮𝗰𝘁𝗲𝗿𝗶𝗼𝗰𝗶𝗻𝘀 𝘄𝗶𝘁𝗵 𝘀𝘁𝗿𝗼𝗻𝗴 𝗮𝗻𝘁𝗶-𝗟𝗶𝘀𝘁𝗲𝗿𝗶𝗮
- 𝗡𝗲𝘄 𝗽𝗮𝘁𝗲𝗻𝘁 𝗴𝗿𝗮𝗻𝘁𝗲𝗱 𝗶𝗻 𝗜𝗻𝗱𝗶𝗮 𝗳𝘂𝗿𝘁𝗵𝗲𝗿 𝘀𝘁𝗿𝗲𝗻𝗴𝘁𝗵𝗲𝗻𝗶𝗻𝗴 𝗦𝘆𝗻𝗴𝘂𝗹𝗼𝗻’𝘀 𝗴𝗹𝗼𝗯𝗮𝗹 𝗯𝗮𝗰𝘁𝗲𝗿𝗶𝗼𝗰𝗶𝗻 𝗜𝗣 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 We are pleased to announce that the 𝗜𝗻𝗱𝗶𝗮𝗻 𝗣𝗮𝘁𝗲𝗻𝘁 𝗢𝗳𝗳𝗶𝗰𝗲 𝗵𝗮𝘀 𝗴𝗿𝗮𝗻𝘁𝗲𝗱 Syngulon 𝗜𝗻𝗱𝗶𝗮𝗻 𝗣𝗮𝘁𝗲𝗻𝘁 𝗡𝗼. 𝟱𝟵𝟵𝟮𝟵𝟯, entitled: “𝗠𝗲𝘁𝗵𝗼𝗱𝘀 𝗮𝗻𝗱 𝗖𝗼𝗺𝗽𝗼𝘀𝗶𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗠𝗮𝗸𝗶𝗻𝗴 𝗕𝗮𝗰𝘁𝗲𝗿𝗶𝗼𝗰𝗶𝗻𝘀 𝗮𝗻𝗱 𝗔𝗻𝘁𝗶𝗺𝗶𝗰𝗿𝗼𝗯𝗶𝗮𝗹 𝗣𝗲𝗽𝘁𝗶𝗱𝗲𝘀.” This new grant further expands the
- Syngulon at BioLogical Control Systems 2026 in Oxford We are pleased to announce that Alex Quintero Yanes, CTO of Syngulon will attend BioLogical Control Systems 2026, taking place at the University of Oxford on 14–15 September 2026. The conference will bring together researchers and industry partners working at the intersection of biology, control engineering and synthetic biology, with discussions spanning gene circuit design, biological process optimisation and the development of more predictable and robust biological
- A first for Syngulon at BioFIT 2026! For the first time, Syngulon will be exhibiting at #BioFIT December 10-11 in Marseille, France. #BioFIT is the leading European partnering event for early-stage deals and investment in Life Sciences. Kenny Petit, PhD, Estelle Plant, PhD and Guy Hélin will be attending and look forward to meeting biotech, Animal Health and pharma to explore licensing and partnering opportunities around Syngulon’s technologies. In particular, we will be happy to discuss how our 𝗮𝗻𝘁𝗶𝗯𝗶𝗼𝘁𝗶𝗰-𝗳𝗿𝗲𝗲
- 𝗘𝘀𝘁𝗲𝗹𝗹𝗲’s perspective captures what Syngulon’s “𝗦𝘁𝗮𝗿𝘁𝘂𝗽 𝗶𝗻 𝘁𝗵𝗲 𝗟𝗮𝗯𝘀” approach is all about: connecting academic expertise with real-world biotechnology challenges and customer needs. We are pleased to support this transition and look forward to the scientific work and new developments ahead.
- We are delighted to welcome Estelle Plant to the Syngulon team as our new 𝗥&𝗗 𝗣𝗿𝗼𝗷𝗲𝗰𝘁 𝗠𝗮𝗻𝗮𝗴𝗲𝗿! 𝗘𝘀𝘁𝗲𝗹𝗹𝗲 will be based in 𝗣𝗿𝗼𝗳𝗲𝘀𝘀𝗼𝗿 𝗟𝗮𝘂𝗿𝗲𝗻𝗰𝗲 𝗩𝗮𝗻 𝗠𝗲𝗹𝗱𝗲𝗿𝗲𝗻’s laboratory at the Université libre de Bruxelles (𝗨𝗟𝗕), where she will contribute to the coordination and advancement of Syngulon’s R&D projects. Her arrival further strengthens our collaborative approach, bringing together scientific expertise, academic research and biotechnology innovation. Welcome to the team, 𝗘𝘀𝘁𝗲𝗹𝗹𝗲!
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.